Piflufolastat F-18: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Piflufolastat F-18. Educational only — not medical advice.
Labeled uses
PYLARIFY TRUVU is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer: with suspected metastasis who are candidates for initial definitive therapy with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level
Source: FDA labeling via NIH DailyMed (set 121c1cb8…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.